The Committee for Medicinal Products for Human Use (CHMP) decided that Avonex’ s benefits are greater than its risks for treatment of patients diagnosed with relapsing MS, or with a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids.